A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature
Author(s) -
Anna L. Hutchinson,
Yi Ling Tan,
Giselle KidsonGerber
Publication year - 2013
Publication title -
case reports in hematology
Language(s) - English
Resource type - Journals
eISSN - 2090-6560
pISSN - 2090-6579
DOI - 10.1155/2013/703027
Subject(s) - medicine , rituximab , immunosuppression , intensive care medicine , cytomegalovirus , opportunistic infection , intensive care unit , pediatrics , immunology , lymphoma , human immunodeficiency virus (hiv) , herpesviridae , viral disease
This case report describes a patient with an idiopathic acquired Factor VIII inhibitor and severe bleeding. She was treated with rituximab after failing first-line treatment with steroids and cyclophosphamide. Two months following rituximab treatment, our patient developed a succession of severe opportunistic infections requiring intensive care unit admission. Over a period of 12 weeks she required treatment for Pseudomonas aeruginosa septicaemia, herpes simplex gingivostomatitis and pharyngotonsillitis, clostridium difficile-related diarrhoea, systemic cytomegalovirus infection, pneumocystis jiroveci, and invasive pulmonary aspergillosis lung infections. After significant rehabilitation, the patient was finally discharged following a 5-month admission. This case highlights the complexity of balancing a life-threatening condition with the side effects of treatment. It also raises the issue of routine prophylaxis for immunosuppression in nonmalignant conditions, which will become a common dilemma with the expanding indications for rituximab use.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom